| Full Name | Mehran Moradi |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 2600 N Tx-118, Alpine, Texas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336571439 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | Q8307 (Texas) | Primary |
| Entity Name | Brewster Emergency Medicine Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538218771 PECOS PAC ID: 1254430481 Enrollment ID: O20070628000245 |
News Archive
Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced the U.S. Food and Drug Administration (FDA) has agreed to the Company's updated product specifications for SURFAXIN® (lucinactant) Intratracheal Suspension which was approved for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS.
Researchers from the Vaccine and Infectious Disease Division at the Fred Hutchinson Cancer Research Center, USA, have revealed that adaptive evolution in the antigenic regions facilitates seasonal coronaviruses to escape the host immune responses and to cause recurrent infections.
Asterand plc, a leading provider of human tissue and human tissue-based services to pharmaceutical and biotechnology companies engaged in drug discovery research, today announced that it has extended its collaboration with Bristol-Myers Squibb Company (NYSE: BMY) for access to Asterand's products and services for up to three years.
Covering a patient area of 400 square miles, a new accountable care organization (ACO) affiliation between UT Southwestern Clinically Affiliated Physicians and Genesis Accountable Physician Network is set to offer exceptional and comprehensive care to patients across North Texas.
› Verified 9 days ago
| Entity Name | Navarro Emergency Physicians Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851523252 PECOS PAC ID: 1254487861 Enrollment ID: O20090923000744 |
News Archive
Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced the U.S. Food and Drug Administration (FDA) has agreed to the Company's updated product specifications for SURFAXIN® (lucinactant) Intratracheal Suspension which was approved for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS.
Researchers from the Vaccine and Infectious Disease Division at the Fred Hutchinson Cancer Research Center, USA, have revealed that adaptive evolution in the antigenic regions facilitates seasonal coronaviruses to escape the host immune responses and to cause recurrent infections.
Asterand plc, a leading provider of human tissue and human tissue-based services to pharmaceutical and biotechnology companies engaged in drug discovery research, today announced that it has extended its collaboration with Bristol-Myers Squibb Company (NYSE: BMY) for access to Asterand's products and services for up to three years.
Covering a patient area of 400 square miles, a new accountable care organization (ACO) affiliation between UT Southwestern Clinically Affiliated Physicians and Genesis Accountable Physician Network is set to offer exceptional and comprehensive care to patients across North Texas.
› Verified 9 days ago
| Entity Name | Concord Medical Group Of Texas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750790762 PECOS PAC ID: 7810117223 Enrollment ID: O20141007002567 |
News Archive
Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced the U.S. Food and Drug Administration (FDA) has agreed to the Company's updated product specifications for SURFAXIN® (lucinactant) Intratracheal Suspension which was approved for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS.
Researchers from the Vaccine and Infectious Disease Division at the Fred Hutchinson Cancer Research Center, USA, have revealed that adaptive evolution in the antigenic regions facilitates seasonal coronaviruses to escape the host immune responses and to cause recurrent infections.
Asterand plc, a leading provider of human tissue and human tissue-based services to pharmaceutical and biotechnology companies engaged in drug discovery research, today announced that it has extended its collaboration with Bristol-Myers Squibb Company (NYSE: BMY) for access to Asterand's products and services for up to three years.
Covering a patient area of 400 square miles, a new accountable care organization (ACO) affiliation between UT Southwestern Clinically Affiliated Physicians and Genesis Accountable Physician Network is set to offer exceptional and comprehensive care to patients across North Texas.
› Verified 9 days ago
| Entity Name | Longhorn Emergency Medical Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649669672 PECOS PAC ID: 4486971041 Enrollment ID: O20150320000152 |
News Archive
Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced the U.S. Food and Drug Administration (FDA) has agreed to the Company's updated product specifications for SURFAXIN® (lucinactant) Intratracheal Suspension which was approved for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS.
Researchers from the Vaccine and Infectious Disease Division at the Fred Hutchinson Cancer Research Center, USA, have revealed that adaptive evolution in the antigenic regions facilitates seasonal coronaviruses to escape the host immune responses and to cause recurrent infections.
Asterand plc, a leading provider of human tissue and human tissue-based services to pharmaceutical and biotechnology companies engaged in drug discovery research, today announced that it has extended its collaboration with Bristol-Myers Squibb Company (NYSE: BMY) for access to Asterand's products and services for up to three years.
Covering a patient area of 400 square miles, a new accountable care organization (ACO) affiliation between UT Southwestern Clinically Affiliated Physicians and Genesis Accountable Physician Network is set to offer exceptional and comprehensive care to patients across North Texas.
› Verified 9 days ago
| Entity Name | Concord North Texas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952761173 PECOS PAC ID: 2860791688 Enrollment ID: O20160429000472 |
News Archive
Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced the U.S. Food and Drug Administration (FDA) has agreed to the Company's updated product specifications for SURFAXIN® (lucinactant) Intratracheal Suspension which was approved for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS.
Researchers from the Vaccine and Infectious Disease Division at the Fred Hutchinson Cancer Research Center, USA, have revealed that adaptive evolution in the antigenic regions facilitates seasonal coronaviruses to escape the host immune responses and to cause recurrent infections.
Asterand plc, a leading provider of human tissue and human tissue-based services to pharmaceutical and biotechnology companies engaged in drug discovery research, today announced that it has extended its collaboration with Bristol-Myers Squibb Company (NYSE: BMY) for access to Asterand's products and services for up to three years.
Covering a patient area of 400 square miles, a new accountable care organization (ACO) affiliation between UT Southwestern Clinically Affiliated Physicians and Genesis Accountable Physician Network is set to offer exceptional and comprehensive care to patients across North Texas.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mehran Moradi, DO 2600 N Tx-118, Alpine, TX 79830 Ph: (432) 837-3447 | Mehran Moradi, DO 2600 N Tx-118, Alpine, TX 79830 Ph: (432) 837-3447 |
News Archive
Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced the U.S. Food and Drug Administration (FDA) has agreed to the Company's updated product specifications for SURFAXIN® (lucinactant) Intratracheal Suspension which was approved for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS.
Researchers from the Vaccine and Infectious Disease Division at the Fred Hutchinson Cancer Research Center, USA, have revealed that adaptive evolution in the antigenic regions facilitates seasonal coronaviruses to escape the host immune responses and to cause recurrent infections.
Asterand plc, a leading provider of human tissue and human tissue-based services to pharmaceutical and biotechnology companies engaged in drug discovery research, today announced that it has extended its collaboration with Bristol-Myers Squibb Company (NYSE: BMY) for access to Asterand's products and services for up to three years.
Covering a patient area of 400 square miles, a new accountable care organization (ACO) affiliation between UT Southwestern Clinically Affiliated Physicians and Genesis Accountable Physician Network is set to offer exceptional and comprehensive care to patients across North Texas.
› Verified 9 days ago
Dr. Anthony Sforza, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: Hc 65, 21-b, Alpine, TX 79830 Phone: 432-364-2223 Fax: 432-364-2299 |